Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Jason Holt

Interventional Pain Medicine Fayetteville, AR Medical Doctor

NPI 1932328267 CMS profile 1215468

1100 N College Ave, Fayetteville, AR 72703

Open in the dashboard

General payments

$1,780

107 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Jason Holt of Fayetteville, AR is reported in the CMS Open Payments database as having received $1,780 across 107 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 33rd percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $130 3
2023 General $257 14
2022 General $341 18
2021 General $282 20
2020 General $284 22
2019 General $487 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jason Holt
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Jason Holt were reported at $0. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Jason Holt Interventional Pain Medicine median Middle half National median
2019 $487 $684 $216–$2,079 $163
2020 $284 $382 $122–$1,109 $114
2021 $282 $552 $167–$1,554 $132
2022 $341 $605 $187–$1,924 $149
2023 $257 $671 $195–$1,915 $160
2024 $130 $684 $206–$1,837 $164
2025 $0 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Medtronic, Inc. $648 40 payments
  2. Medtronic USA, Inc. $618 45 payments
  3. Boston Scientific Corporation $118 7 payments
  4. Curonix LLC $98 1 payment
  5. Collegium Pharmaceutical, Inc. $66 4 payments
  6. Midsouth Orthopedics $54 1 payment
  7. SPR Therapeutics, Inc $40 2 payments
  8. Vertos Medical, Inc. $33 1 payment
  9. Nevro Corp. $32 2 payments
  10. Nalu Medical, Inc. $24 1 payment
  11. Other $49 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $1,780 107 payments
Products named General payments · program years 2019–2024
  1. INTELLIS Spinal Cord Neurostimulation $394 25 payments
  2. VANTA ADAPTIVESTIM $240 12 payments
  3. INTELLIS ADAPTIVESTIM $180 12 payments
  4. INTELLIS Spinal Cord Neurostimulation $160 13 payments
  5. ADAPTIVESTIM $156 13 payments
  6. PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A $98 1 payment
  7. GENERAL PAIN MANAGEMENT $69 5 payments
  8. RESTORE $68 7 payments
  9. SPRINT PNS System $40 2 payments
  10. Vanta $37 1 payment
  11. Other $279 15 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

1,723

Median for Interventional Pain Management: 1,220

Drug cost

$61,574

Median for Interventional Pain Management: $39,344

Branded share of claims

30.6%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Buprenorphine Generic 78 $20,834
Belbuca Buprenorphine Hcl Brand 15 $9,240
Oxycontin Oxycodone Hcl Brand 14 $8,187
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 383 $7,890
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 116 $3,501
Pregabalin Generic 167 $3,014
Gabapentin Generic 263 $2,860
Tramadol Hcl Generic 192 $1,657
Oxycodone Hcl Generic 56 $921
Duloxetine Hcl Generic 81 $700

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 43 billing codes

Paid by Medicare

$181,291

Of which drugs: $7,036

Medicare patients

391

Average age 75

Services billed

15,362

246 women, 145 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 34%
Ischemic heart disease 32%
Chronic kidney disease 27%
Diabetes 26%
COPD 20%
Heart failure 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 138 317 $1,719
Injection, methylprednisolone acetate, 1 mg J1010 Office 170 13,241 $1,325
Injection, methylprednisolone acetate, 80 mg J1040 Office 75 81 $547

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

107 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record